Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis

Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis

Uma Ramaswami,1 Michael Beck,2 Derralynn Hughes,1 Christoph Kampmann,2 Jaco Botha,3 Guillem Pintos-Morell,4 Michael L West,5 Dau-Ming Niu,6 Kathy Nicholls,7,8 Roberto Giugliani9 On behalf of the FOS Study Group 1Royal Free London NHS Foundation Trust, Lysosomal Disorders Unit, Inst...

Full description

Bibliographic Details
Main Authors: Ramaswami U, Beck M, Hughes D, Kampmann C, Botha J, Pintos-Morell G, West ML, Niu DM, Nicholls K, Giugliani R
Format: Article
Language:English
Published: Dove Medical Press 2019-10-01
Series:Drug Design, Development and Therapy
Subjects:
Agalsidase alfa
Enzyme replacement therapy
Fabry disease
Cardio-renal outcomes
Online Access:https://www.dovepress.com/cardio--renal-outcomes-with-long--term-agalsidase-alfa-enzyme-replacem-peer-reviewed-article-DDDT

Internet

https://www.dovepress.com/cardio--renal-outcomes-with-long--term-agalsidase-alfa-enzyme-replacem-peer-reviewed-article-DDDT

Similar Items